Merck MRK recently intensified its acquisition strategy, actively pursuing deals to enhance its development pipeline and ...

Gilead Sciences, a heavyweight in the biotech sector, continues to demonstrate strong relative strength trading just 5% below its 52-week high, compared with 16% for the SPDR Biotech ETF. The stock ...